Document:

Exhibit 10.5

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [...***...], HAS BEEN OMITTED BECAUSE ARTARA THERAPEUTICS, INC. HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY
DISCLOSED.

 

SPONSORED
RESEARCH AND LICENSE AGREEMENT

 

This Sponsored Research
and License Agreement (this “Agreement”) is entered into on November 28, 2018 (the “Effective Date”),
by and between ArTara, Inc. located at 1 Little West 12th Street, New York, NY 10014 (“ArTara”),
and The University of Iowa, located at c/o Division of Sponsored Programs, 2 Gilmore Hall, Iowa City, IA 52242 (“University”).
ArTara and University may individually be referred to herein as a “Party,” and collectively as “Parties.”

 

WI T N E S S E T H:

 

WHEREAS, ArTara
is engaged in the development of pharmaceutical products for the treatment of serious rare diseases;

 

WHEREAS, University
is engaged in clinical research to improve the diagnosis and treatment of lymphangioma (LM) using OK-432 (as defined below),
a pharmaceutical product not approved by regulatory authorities in the United States;

 

WHEREAS, University
is engaged in a clinical research Program (as defined below) and with Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi 2-Chome,
Chuo-ku, Tokyo, 103-8324 Japan, and its wholly-owned subsidiary, Chugai Pharma U.S.A, LLC 300 Connell Drive, Suite 3100,
Berkeley Heights, New Jersey 07922 (collectively “Chugai”), the product manufacturer;

 

WHEREAS, Principal
Investigator (as defined below) of the Program is an employee of the University and holds the IND (as defined below) approved by
the FDA (as defined below) for OK-432 under BB-IND#5266;

 

WHEREAS, ArTara
wishes to develop and submit for regulatory approval, TARA-002, a proposed product that will be biosimilar to OK-432;

 

WHEREAS, ArTara
wishes to use the Program Data (as defined below) collected from the Program, conduct research analysis of the Data and potentially
rely on said Program Data to support Regulatory Approvals (as defined below) for TARA-002 in the Territory (as defined below);
and

 

WHEREAS, the
copying, review and analysis of Program Data for the Project (as defined below) contemplated by this Agreement is of mutual interest
and benefit to University and ArTara.

 

NOW, THEREFORE,
in consideration of the foregoing premises and the mutual covenants and agreements contained herein, the Parties agree as follows:

 

Article
One

DEFINITIONS

 

		1.1	“Affiliates” of a person or entity means any other entity which (directly or
indirectly) is controlled by, controls or is under common control with such person or entity. For the purposes of this definition,
the term “control” (including, with correlative meanings, the terms “controlled by” and “under common
control with”) as used with respect to an entity will mean (i) in the case of a corporate entity, direct or indirect ownership
of voting securities entitled to cast at least fifty percent (50%) of the votes in the election of directors, or (ii) in the case
of a non-corporate entity, direct or indirect ownership of at least fifty percent (50%) of the equity interests with the power
to direct the management and policies of such entity, provided that if local law restricts foreign ownership, control will be established
by direct or indirect ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests.

 

    	 	1	 

     

    

 

		1.2	“CRO” means a contract research organization selected by ArTara to assist in
the Project as approved by the University and/or Principal Investigator, such approval not to be unreasonably delayed or withheld.

 

		1.3	“FDA” means the United States Food and Drug Administration.

 

		1.4	“Field” means all therapeutic, diagnostic and prophylactic uses of the Product(s).

 

		1.5	“First Commercial Sale” means the first sale for use or consumption for
which revenue has been recognized of Product in a country or territory after all required Regulatory Approvals for commercial sale
of Product have been obtained in such country or territory.

 

		1.6	“ICH-GCP’s” means the International Conference on Harmonization and Good
Clinical Practice Guidelines as adopted in the applicable FDA regulations.

 

		1.7	“Indication” means treatment of lymphangioma (also known as lymphatic malformations)
in humans.

 

		1.8	“IND” means University filed investigational new drug application on file with
the FDA (BB-IND#5266) for OK-432 for the Indication.

 

		1.9	“Net Sales” means, with respect to the Product, the gross invoiced sales price
payable to ArTara and/or its Affiliates and their respective licensees and sublicensees for sales anywhere in the world of the
Product to a third party, less:

 

		(a)	discounts (including cash, quantity and patient program discounts), retroactive price reductions,
charge-back payments and rebates granted to managed health care organizations or to federal, state and local governments, their
agencies, and purchasers and reimbursers or to trade customers;

 

		(b)	credits or allowances actually, not to exceed the original invoice amount, granted upon claims,
damaged goods, rejections or returns of the Product, including the Product returned in connection with recalls or withdrawals;

 

		(c)	freight out, postage, shipping and insurance charges for delivery of the Product if charged separately
and include in the gross receipts; and

 

		(d)	taxes or duties, excluding income taxes and value-added taxes, levied on, absorbed or otherwise
imposed on the sale of the Product, including governmental charges otherwise imposed upon the billed amount, as adjusted for rebates
and refunds, provided that such are included in gross receipts and are paid to and/or its Affiliates and their respective licensees
and sublicensees.

 

    	 	2	 

     

    

 

Net Sales shall be determined in
accordance with generally accepted accounting principles, consistently applied.

 

		1.10	“OK-432” means Picibanil (OK-432), a lyophilized mixture of group A Streptococcus
pyogenes developed by Chugai and that has been approved by applicable Japanese pharmaceutical regulatory authorities for the treatment
of the Indication.

 

		1.11	“Principal Investigator” means Richard Smith, MD

 

		1.12	“Product” shall mean TARA-002 and any similar products.

 

		1.13	“Program” means collectively, the clinical research studies investigating the
efficacy and safety of OK-432 for the Indication conducted by Principal Investigator in collaboration with multiple sites in the
United States and the University expanded access program performed by Principal Investigator designed to improve the diagnosis
and treatment of the Indication using OK-432.

 

		1.14	“Program Data” means the data set forth on Exhibit A including all case reports
forms, source data, and safety data in the possession of or available to University arising from the Program and any other data
and information included in the IND.

 

		1.15	“Project” shall mean the compilation and available statistical analyses of the
Program Data as described in the Project Plan, which is summarized in Section 2.2.

 

		1.16	“Project Documentation” shall mean the documentation created and generated by
ArTara and CRO in the conduct of the Project that incorporates or is based upon Program Data.

 

		1.17	“Project Plan” means the plan for the Project mutually agreed upon by the Parties
as summarized in Section 2.2.

 

		1.18	“Right of Reference” means the authority to rely upon, and otherwise use, an
investigation for the purpose of obtaining Regulatory Approvals, including the ability to make available the underlying raw (source)
data from the investigation for audit, if necessary.

 

		1.19	“Regulatory Approvals” means the medical, technical and scientific licenses,
registrations, authorizations and approvals (including without limitation, approvals of IND’s, New Drug Applications (“NDA’s”)
and equivalents, supplements and amendments, pre- and post- approvals, pricing and third-party reimbursements approvals and labeling
approvals) for the development and commercialization of pharmaceutical products.

 

		1.20	“Regulatory Authorities” means any applicable national, regional, state or local
regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the development, manufacture,
distribution, marketing, promotion, offer for sale, use, import, export or sale of a pharmaceutical product in a regulatory jurisdiction.

 

		1.21	“Regulatory Filings” means collectively, IND’s, Product License Applications,
Drug Master Files,
NDA’s, Biological License Applications (“BLAs”) including supportive and annual filings and/or any other equivalent
or comparable filings as may be required by Regulatory Authorities to obtain Regulatory Approvals.

 

		1.22	“Royalty” means the royalty on Net Sales of Product in the Indication, as set
forth in Article Three below.

 

    	 	3	 

     

    

 

		1.23	“TARA-002” means the ArTara pharmaceutical product intended to be similar to
or biosimilar to OK-432.

 

		1.24	“Territory” means worldwide.

 

Article
Two

PROJECT

 

2.1          Performance of Project. The University and/or Principal Investigator together with ArTara and the CRO will
conduct the Project in accordance with the Project Plan and will use all reasonable endeavors consistent with their expertise to
successfully complete the Project. It is the goal of the Project to use the Program Data as clinical support for Product Regulatory
Filings and to gain approval to commercialize the Product for the Indication in the Territory.

 

2.2          Project Plan. The Project Plan as approved by each of the Parties may be modified or amended only upon mutual
agreement of each of the Parties. The Project will consist of three phases:

 

		(a)	Phase I: University and/or Principal Investigator will provide access to the Program Data
to ArTara and the CRO at the University’s facilities. ArTara and the CRO will be allowed to make complete copies of the original
Program Data for the purposes of off-site data entry and storage, all as and only to the extent needed to support ArTara’s
efforts to accomplish the Project. University will provide ArTara and CRO the opportunity to examine the originals of medical records
and supporting records for the Program Data at the University during normal business hours and at mutually agreeable times. University
and Principal Investigator will also provide to ArTara contact information for other participating investigators and research sites
that have contributed data to the Program. University will retain all Program Data for the sooner to occur of a New Drug Application
(NDA) for the Product being approved or ten (10) years from the Effective Date. ArTara will bear any costs related to necessary
long-term on or off-site storage of the Program Data, medical records and/or supporting records. ArTara understands that separate
engagement agreements may be required by collaborating third party entities and associated principal investigators and University
will assist ArTara in obtaining such agreements. It is understood that the goal of Phase I is a feasibility analysis of the Program
Data to support Regulatory Filings in the United States.

 

		(b)	Phase II: University recognizes that because of ArTara’s unfamiliarity with the Program
Data database, assistance from the Principal Investigator and other research and medical employees of the University may from time
to time be

needed for ArTara to query and analyze the Program Data database as needed to achieve successful presentation to applicable Regulatory
Authorities and submission of Regulatory Filings. ArTara will endeavor to minimize University resources required during Phase II.
The goal of Phase II will be to compile the Project Documentation.

 

		(c)	Phase III: CRO will convert Program Data to eCTD format for submission to Regulatory Authorities.
University recognizes that ArTara may receive specific data requests from Regulatory Authorities in connection with ArTara’s
presentations of Program Data to support Regulatory Filings. University will assist ArTara in responding to such requests for data
or access to source data from Regulatory Authorities. ArTara agrees to notify University of such requests as soon as is practicable.
The goal of Phase III will be filing of a BLA based on Project Documentation and response to Regulatory Authorities.

 

    	 	4	 

     

    

 

		(d)	Phase IV Optional: Upon mutual written agreement of University and ArTara, ArTara may sponsor,
and University may conduct, new Product or Product-related clinical studies (for example, follow-up studies) to support the goal
of the Project or as may be useful for gaining or maintaining Regulatory Approvals for the Product for the Indication. Any such
studies will be at the sole discretion of each Party subject to terms and conditions to be mutually agreed upon in agreements separate
from this Agreement. Richard Smith, MD will be given first consideration as a principal investigator for all new Product
or Product-related clinical studies, in addition to other sites provided final site selection will be based on the best interest
of the Project.

 

		(e)	Phase V: Publication: Collected data from the Project will be used to write a paper by the
University and/or Principal Investigator (the “Publication”) as a follow up to the publication in 2009 (Smith MC,
Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ; OK-432 Collaborative Study Group. Efficacy and safety of OK-432 immunotherapy
of lymphatic malformations. Laryngoscope. 2009Jan;119(1):107-15. doi: 10.1002/lary.20041. PubMed PMID: 19117316). (the “Publication”).
The Publication will be in accordance with the terms in Article 5 herein.

 

2.3          Project Management. During the term of this Agreement, the Principal Investigator and and/or his authorized
representative and ArTara authorized representatives will meet as necessary to consult with one another and discuss the progress
and results of the Project and any modifications to the Project Plan. Consultation by either Party shall be by means of personal
visits, correspondence and telephone calls, all as appear reasonable and necessary and are mutually agreed upon by the Principal
Investigator and ArTara.

 

Article
Three

FUNDING AND PAYMENT

 

3.1          Funding. During the term of the Project in accordance with the Project Plan, ArTara will provide thirty thousand
dollars (US $30,000) per year in funding for the Project, taking into consideration the time spent by University employees required
for the Project. The Parties agree to discuss in good faith potential additional funding required for completion of the Project
as applicable and necessary.

 

3.2          Approval Milestone based on Data Value: Within forty-five (45) days of an approval of the TARA-002 BLA by the FDA,
ArTara will pay a one-time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002’s
BLA filing, as set forth below:

 

	Official Feedback from FDA regarding the Program Data	Milestone
	[...***...]	$[...***...]
	[...***...]	$[...***...]
	[...***...]	$[...***...]
	[...***...]	[...***...]

 

    	 	5	 

     

    

 

3.3          Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no
later than [...***...] following the close of each calendar quarter, pay tiered Royalties based on annual Net Sales of
Product in the Indication as set forth below:

 

	Annual Net Sales of Product for the

 Indication	Annual Royalty Rate Percent Net

 Sales
	$0 - $25,000,000	1.75%
	>$25,000,000 - $50,000,000	2.25%
	>$50,000,000	2.50%

 

3.4          Royalty Reduction. In the event the Regulatory Authorities determine that the Program Data is not sufficient
for Regulatory Approvals on its own and additional pediatric efficacy and safety clinical studies are required, Royalties set forth
above will be reduced by [...***...] percent ([...***...]%).

 

3.5          Sales Milestone Payments. In the event that Annual Net Sales, as detailed in Section 3.3, surpass certain
thresholds, ArTara will make the following payments no later than [...***...] following the close of the calendar quarter
in which each milestone is reached as set forth below:

 

	Annual Net Sales of Product for the 

Indication Exceeds	Milestone Payment
	$25,000,000	$62,500
	$50,000,000	$62,500
	$100,000,000	$125,000

 

3.6          Payments.

 

All payments under Articles 3.2, 3.3 and 3.5 shall be sent to
the following address:

 

Checks will be sent to:

The University of Iowa Research Foundation

ATTN: Accounting

6 Gilmore Hall

112 North Capitol St.

Iowa City, IA 52242-5500

 

Wire transfers will
be sent to:

[...***...]

 

    	 	6	 

     

    

 

ArTara will include
the University of Iowa Research Foundation agreement number 2019- 068, a reference to “Richard Smith, MD, ArTara Sponsored
Research and License Agreement dated November 28, 2018” and purpose of payment with all payments. ArTara will add
all applicable wire transfer fees to wire transfer payments.

 

All other payments shall
be sent to the following address:

 

The University of Iowa

c/o Grant Accounting Office

118 S. Clinton St.

Iowa City, IA 52242

Article
Four

DATA AND INTELLECTUAL PROPERTY

 

		4.1	Program Data and Project Documentation.

 

(a)              
Program Data. Access to all original Program Data shall be provided to ArTara and the CRO at University’s facilities
in accordance with the Project Plan for the purposes of review and copying as and only to the extent needed to support ArTara’s
efforts to accomplish the Project. As between ArTara and the University, ownership of all Program Data is hereby retained by the
University.

 

(b)              
Project Documentation. All Project Documentation shall be owned by ArTara to the extent publishable in accordance
with Section 5 herein, except that ownership of any and all Program Data incorporated into Project Documentation shall as between
ArTara and the University remain with the University. University may use all Project Documentation without royalty obligation for
patient care and for its own internal teaching, research, and educational purposes, for publication to the extent permitted under
Section 5 herein, and for the purpose of complying with any federal, state, or local laws or regulations. All medical records that
support the Program Data and Project Documentation shall remain the property of the University.

 

		4.2	License. University hereby grants to ArTara an exclusive license to use the Program
Data solely for the Project and in Regulatory Filings in the Field in the Territory.

 

		4.3	Right of Reference and IND Assignment. University hereby grants to ArTara an exclusive
Right of Reference to all Program Regulatory Filings by University in support of the Product. Upon written request of ArTara, University
will assign the IND to ArTara.

 

		4.4	Intellectual Property. All intellectual property or patentable inventions arising
out of or in connection with the Project which is discovered or invented solely by the University and/or Principal Investigator
shall be the exclusive property of the University (“University Intellectual Property”). All intellectual property or
patentable inventions arising out of or in connection with the Project which is discovered or invented solely by or on behalf of
ArTara shall be the exclusive property of ArTara. All intellectual property or patentable inventions arising out of or in connection
with the Project that are discovered or invented jointly by Principal Investigator and ArTara shall be considered Joint Intellectual
Property and shall be jointly owned by the University and ArTara.

 

    	 	7	 

     

    

 

Article
Five

CONFIDENTIAL INFORMATION; PUBLICATION

 

5.1          Confidentiality. During the term of this Agreement and for a period of seven (7) years after its termination
or expiration each Party (the “Receiving Party”) shall maintain in confidence and, except as authorized by this Agreement,
not use any know-how, data, processes, techniques, formulas, test data and other information disclosed by the other Party (the
 “Disclosing Party”) and which for any of the foregoing, if written, is marked “Confidential” by the Disclosing
Party or, if verbal or visual, is identified in writing as “Confidential” at the time of disclosure and reduced to
writing by the Disclosing Party within thirty (30) days of the verbal or visual disclosure (“Confidential Information”).

 

5.2          Exceptions. The obligations of confidentiality and non-use set forth in paragraph 5.1 shall not apply to the
extent that it can be established by Receiving Party that the information:

 

(a)   
was already known to Receiving Party without restriction at the time of disclosure;

 

(b)   
was generally available to the public or otherwise part of the public domain at the time of its disclosure;

 

(c)   
became generally available to the public or otherwise part of the public domain after its disclosure to Receiving Party
through no breach of this Agreement by Receiving Party;

 

(d)   
was disclosed to Receiving Party without restriction by a third party who had no known obligation to not to disclose such
information;

 

(e)   
was independently developed by Receiving Party without the use of Confidential Information;

 

(f)    
was required to be disclosed by operation of law or court order; or

 

(g)   
Disclosing Party gave prior written consent to Receiving Party to disclose such Confidential Information.

 

5.3          Return of Confidential Information. In the event the Disclosing Party requests in writing the return of Confidential
Information, the Receiving Party shall return such Confidential Information to Disclosing Party with the exception of one copy,
which may be retained for archival purposes.

 

5.4          Publication. The University and ArTara each agree to treat matters of authorship of the Publication in a proper
collaborative spirit and following guidelines and policies in accordance with the University of Iowa’s Operations Manual
which may be found at: https://opsmanual.uiowa.edu/.

 

It is anticipated that
employees of the University will be first and senior authors on the Publication, but it is understood that final authorship will
be determined in accordance with all applicable laws and regulations in publication practice, including Section 6002 of the Affordable
Care Act a/k/a Sunshine Act and with ICMJE (International Committee of Medical Journal Editors) guidelines, standard scientific
practice and journal guidelines. University and/or Principal Investigator shall provide ArTara with a copy of any proposed Publication
for review and comment at least [...***...] prior to submission thereof for publication. ArTara shall have [...***...],
after receipt of said copy to object to such proposed Publication because there is Confidential Information which needs protection.
In the event that ArTara makes such objection, University and/or Principal Investigator shall refrain from submitting such Publication
for a maximum of [...***...] from date of receipt of such objection in order for ArTara to file patent application(s)
directed to patentable subject matter contained in the proposed Publication. If in its review, ArTara identifies information it
considers to be its Confidential Information, ArTara may require redaction of that Confidential Information; provided, however,
that ArTara shall not require removal of information necessary for complete and accurate presentation and interpretation of the
Program Data and results. The Publication shall occur within [...***...] of the date the Project is closed or terminated,
or University and/or Principal Investigator shall be free to publish Program Data and results at that time.

 

    	 	8	 

     

    

 

Article
Six

REPRESENTATIONS; INDEMNIFICATION

 

6.1          Representations. University represents:

 

		(a)	The Program is being, and has been, conducted in accordance with all applicable local, state and
federal laws, and regulations, including, but not limited to, the Federal Food, Drug and Cosmetic Act and the regulations of the
FDA, International Conference on Harmonization Good Clinical Practices as adopted in the applicable FDA regulations (“GCP’s”),
and the Form FDA 1572 Statements of Investigators.
	 	 	 

		(b)	The Program is being and has been conducted in accordance with all applicable medical privacy laws
or regulations, including without limitation, by obtaining any required subject informed consent to allow ArTara and ArTara’s
authorized representatives, FDA and other Regulatory Authorities access to and use of enrolled subjects’ medical information
as may be necessary for ArTara to receive and use Program Data under this Agreement.
	 	 	 

		(c)	The clinical studies included in the Program are and have been conducted in accordance with the
applicable protocol associated with the BB-IND#5266 held by the Principal Investigator.
	 	 	 

		(d)	University represents that informed consent was required from all individual subjects prior to
enrollment in the Program, and that the Program was approved by the Institutional Review Board of the University.
	 	 	 

		(e)	University represents that it is authorized to enter into this Agreement and that the terms of
this Agreement are consistent with the rules, regulations, policies and/or guidelines of University.
	 	 	 

		(f)	University represents that to the best of its knowledge and belief there are no outstanding agreements
or assignments which are inconsistent with the rights granted to ArTara pursuant to Article Four.
	 	 	 

		(g)	The Parties shall commence performance of the Project promptly after the date of last signature
of this Agreement and shall perform the Project in accordance with the current state of the laboratory research art and in accordance
with applicable state and federal laws, including export laws, and regulations.
	 	 	 

		(h)	University represents to the best of its knowledge, all information provided to ArTara pursuant
to this Agreement is accurate in accordance with ICH-GCP’s.

 

		(i)	EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, THE UNIVERSITY MAKES NO REPRESENTATION
AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. IN PARTICULAR,
BUT WITHOUT LIMITATION, THE UNIVERSITY MAKES NO REPRESENTATION AND EXTENDS NO WARRANTY CONCERNING WHETHER THE PROGRAM DATA IS ACCURATE
OR COMPLETE. THE PARTIES RECOGNIZE AND AGREE THAT ALL PROGRAM DATA, AND RELATED MATERIALS, DOCUMENTS, AND OTHER INFORMATION, THE
UNIVERSITY MAKES AVAILABLE TO ARTARA AT ANY TIME IN CONNECTION WITH THIS AGREEMENT, ARE MADE AVAILABLE TO ARTARA AS AN ACCOMMODATION,
AND WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY, AS TO THE ACCURACY AND COMPLETENESS
OF SUCH MATERIALS, DOCUMENTS, AND OTHER INFORMATION. ARTARA EXPRESSLY AGREES THAT ANY RELIANCE UPON OR CONCLUSIONS DRAWN FROM THE
PROGRAM DATA SHALL BE AT ARTARA’S OWN RISK TO THE MAXIMUM EXTENT PERMITTED BY LAW AND SHALL NOT GIVE RISE TO ANY LIABILITY
OF OR AGAINST THE UNIVERSITY. ARTARA HEREBY WAIVES AND RELEASES ANY CLAIMS ARISING UNDER THIS AGREEMENT, COMMON LAW OR ANY STATUTE
ARISING OUT OF ANY PROGRAM DATA, RELATED MATERIALS, DOCUMENTS OR INFORMATION PROVIDED TO IT BY THE UNIVERSITY.

 

    	 	9	 

     

    

 

		(j)	University represents, to the best of its knowledge and belief, that neither it nor any of its
officers, directors, employees involved in performing the Project is presently debarred pursuant to the Generic Drug Enforcement
Act of 1992. University shall notify ArTara upon becoming aware of any inquiry or the commencement of any such investigation or
proceeding.

 

6.2          Representations. ArTara represents and warrants:

 

		(a)	It is a company duly organized, existing, and in good standing under the laws of Delaware;

 

		(b)	The execution, delivery, and performance of this Agreement have been authorized by all necessary
corporate action on the part of ArTara and the person signing this Agreement on behalf of ArTara has the authority to do so;

 

		(c)	The making, exercising of any right, or performance of any obligation under this Agreement does
not violate any separate agreement it has with a third party, and in so acting, ArTara will not breach the terms and conditions
of this Agreement or fail to comply with applicable laws, regulations, and court orders;

 

		(d)	It is not a party to any agreement or arrangement that would prevent it from performing its duties
and fulfilling its obligations to the University under this Agreement;

 

		(e)	It has and will maintain at the time specified in Article 7 herein, the insurance coverage called
for in Article 7;

 

		(f)	It will obtain any additional licenses from any third party needed to perform and fulfill its duties
and obligations under this Agreement; and

 

		(g)	There is no pending litigation and no threatened claims against it that could impair its ability
or capacity to perform and fulfill its duties and obligations under this Agreement.

 

6.3          Indemnification by ArTara. To the extent permitted by law, ArTara agrees to defend, indemnify and hold the
University of Iowa Research Foundation, the University, the State of Iowa, the University’s Board of Regents, their respective
affiliates, trustees, officers, directors, faculty, staff, students, successors, assigns, independent contractors, agents and
employees including but not limited to Principal Investigator (“University Indemnitees”), harmless from and against
any and all liability, loss, expense, reasonable adjudicated attorneys’ fees, or claims for injury or damages arising out
of the use of the Program Data by ArTara and its Affiliates and subcontractors including but not limited to the CRO involved in
the Project, but only in proportion to and to the extent such liability, loss, expense, attorneys’ fees, or claims for injury
or damages are caused by or result from the negligent or acts or omissions of ArTara, its officers, agents, employees, subcontractors,
the CRO or Affiliates.

 

    	 	10	 

     

    

 

6.4          No Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT
IN A DIRECT ACTION BETWEEN THE PARTIES FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION,
LOSS OF PROFITS) SUFFERED BY THE OTHER PARTY.

 

Article
Seven

INSURANCE

 

7.1          ArTara, Affiliates, and sublicensees will obtain and maintain commercial general liability insurance with a reputable and
financially secure insurance carrier prior to clinical testing, making, using, importing, offering to sell, or selling any licensed
Product or engaging in any other act involving any licensed Product or the patent rights, if such act could possibly create risk
of a claim against University Indemnitees for personal injury or property damage.

 

		(a)	The insurance will identify University Indemnitees as additional insureds and will provide that
the carrier will notify University in writing at least [...***...] prior to cancellation, non-renewal, or material change
in coverage. Should ArTara fail to obtain replacement insurance providing comparable coverage within such [...***...]
period, University will have the right to termination this Agreement effective as of the end of the [...***...] period
without notice or any additional cure period.

 

		(b)	The insurance will include coverage for product liability with a minimum of [...***...]
dollars ($[...***...]) per occurrence and [...***...] dollars ($[...***...]) annual aggregate, coverage
for contractual liability, clinical trials liability if any such trial is performed, bodily injury and property damage, including
completed operations, personal injury, coverage for contractual employees, blanket contractual and products, and all other coverages
standard for such policies. Such insurance will additionally include errors and omissions insurance with a minimum of [...***...]
dollars ($[...***...]) per occurrence.

 

		(c)	Insurance policies purchased to comply with this Article Seven will be kept in force for at least
[...***...] after the last sale of licensed Product.

 

7.2          At University’s request, such request to be made no more than annually, ArTara will provide University with a certificate
of insurance and notices of subsequent renewals for its insurance and that of Affiliates extended rights under this Agreement and
of sublicensees.

 

7.6          The
specified minimum coverages and other provisions of this Article Seven do not constitute a limitation on ArTara’s obligation
to indemnify the University Indemnitees under this Agreement.

 

    	 	11	 

     

    

 

Article
Eight

TERM AND TERMINATION

 

8.1          Term. This Agreement may be terminated by ArTara upon thirty (30) days prior written notice to University.

 

8.2          Termination by Either Party. Either Party may terminate the Project and all commitments and obligations with
respect thereto, subject to Section 8.3 herein, upon thirty (30) days written notice to the other Party. In the event of any termination
of the Project by University, (a) University agrees to complete Phase I and II of the Project, and (b) ArTara will continue to
provide annual funding until the completion of Phase II. Upon termination of the Project by ArTara this Agreement will terminate
subject to Section 8.3 and ArTara will reassign to University the IND if assignment thereof previously occurred pursuant to Section
4.3.

 

8.3          Survival. Termination of the Project for any reason shall not relieve any Party of any obligation that accrued
under this Agreement prior to termination. The provisions of Article Three, Article Four, Article Five, Sections 6.3 and 6.4, and
Articles Seven through Nine shall survive termination of the Project by University. The provisions of Article Five, Sections 6.3
and 6.4, Article Seven, Section 8.3 and Article Nine shall survive termination of the Project and this Agreement by ArTara.

 

Article
Nine

MISCELLANEOUS

 

9.1          Force Majeure. University will not be liable for any failure to perform as required by this Agreement, if
the failure to perform is caused by circumstances reasonably beyond University’s control, such as labor disturbances or labor
disputes of any kind, accidents, failure of any governmental approval required for full performance, civil disorders or commotions,
acts of aggression, acts of God, energy or other conservation measures, explosions, failure of utilities, mechanical breakdowns,
material shortages, disease, thefts, or other such occurrences.

 

9.2          Publicity. No Party will use directly or by implication the name of any other Party, or the name of any employee
thereof without prior written notification and agreement of the named Party for promotional, marketing or advertising purposes.
Notwithstanding the foregoing, nothing herein shall prevent either Party from disclosing the existence of this Agreement, the identities
of the Parties, or the basic nature and scope of the purpose of this Agreement.

 

9.3          Notices. Any Notice required to be given pursuant to this Agreement shall be made by personal delivery or,
if by mail, then by registered or certified mail, return receipt requested, by one Party to the other Party at the following addresses.

 

In the case of ArTara,
Notice should be sent to:

 

ArTara Therapeutics

1 Little West 12th Street

NY, NY 10014

 

    	 	12	 

     

    

 

Attention: Jesse Shefferman

 

In the case of University, Notice should be sent to:

 

The University of Iowa

c/o Division of Sponsored Programs

2 Gilmore Hall

Iowa City, IA 52242

Attention: [...***...]

 

9.4          Governing Law. This Agreement shall be governed by the laws of the State of Iowa.

 

9.5          Assignment. No Party may assign any rights under this Agreement or delegate any duties hereunder without the
prior written consent of the other Party.

 

9.6          Independent Contractors. The relationship between ArTara and the University created by this Agreement shall
be one of an independent contractor and no Party shall have the authority to bind or act as agent for the other Party.

 

9.7          Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the
subject matter hereof and supersedes all prior agreements and understandings between the Parties (whether written or verbal) relating
to said subject matter.

 

9.8          Severability. Whenever possible each provision of this Agreement shall be interpreted in such a manner as
to be effective and valid under applicable law but should any provision of this Agreement be held to be prohibited or invalid under
applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating
the remainder of this Agreement. However, if such provision is deemed significant and its invalidity would substantially alter
the basis of this Agreement, the Parties will negotiate in good faith to amend the provisions of this Agreement to give effect
to the original intent of the parties.

 

9.9          Waiver. No provision of this Agreement shall be waived by any act or omission of the Parties or their agents
or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the
waiving Party.

 

9.10        Counterparts. This Agreement may be signed in any number of counterparts, including in PDF format, each of
which shall be an original, with the same effect as though the signatures hereto and thereto were on the same instrument.

 

9.11        Section Headings. The recitals and descriptive headings of this Agreement are for convenience only and shall
be of no force or effect in interpreting any of the provisions of this Agreement.

 

    	 	13	 

     

    

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be duly executed by an authorized official as of the day and year first above written.

 

	ARTARA THERAPEUTICS, INC.	 
	 	 
	 	 
	/s/ Jesse Shefferman	 
	By: Jesse Shefferman

Title: Chief Executive Officer	 
	 	 
	 	 
	THE UNIVERSITY OF IOWA	 
	 	 
	 	 
	/s/ Wendy Beaver	 
	By: Wendy Beaver

Title: Executive Director, Division of Sponsored Programs	 
	 	 
	 	 
	READ & ACKNOWLEDGED BY PRINCIPAL INVESTIGATOR	 
	 	 
	 	 
	/s/ Richard Smith	 
	By: Richard Smith, M.D.

Title: Professor of Otolaryngology Head and Neck Surgery	 

 

    	 	14	 

     

    

 

EXHIBIT
A

PROGRAM DATA

 

[...***...]

 

    	 	15Exhibit 10.6

 

CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [...***...], HAS BEEN OMITTED BECAUSE ARTARA THERAPEUTICS, INC. HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ARTARA THERAPEUTICS, INC. IF PUBLICLY
DISCLOSED.

 

LICENSE
AGREEMENT

 

This License Agreement
(“Agreement”) is entered into as of December 22, 2017 (“Effective Date”), by and between The
Feinstein Institute for Medical Research, a not-for-profit corporation organized and existing under the laws of New York,
having an office and place of business at 350 Community Drive, Manhasset, NY 11030 (“Licensor”) and ArTara
Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having an office and place of business
at 302a West 12th Street, Suite 254, New York, NY 10014 (“Licensee”).

 

STATEMENT

 

Licensor is the owner by assignment of the
Agreement Patents (as defined below) which relate to treatment of fatty liver disease in humans. Licensee wishes to acquire an
exclusive license in the Field (as defined below) from Licensor with respect to such patent rights.

 

NOW, THEREFORE, in consideration of the
promises and mutual covenants, conditions and limitations herein contained and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, Licensor and Licensee agree as follows:

 

	1.	Definitions

 

	1.01	“Agreement Patents” means the patent listed on Appendix A, together with any and all reissues, reexaminations,
renewals, continuations, extensions and any application claiming priority to the patent listed on Appendix A or the patent
application on which it is based.

 

    -1-

     

    

 

 

		1.02	“Affiliate” means any entity that, directly or indirectly, through one or more intermediates, controls,
is controlled by, or is under common control with Licensee. For the purposes of this definition, control shall mean the direct
or indirect ownership of at least Fifty Percent (50%) of (i) the stock shares entitled to vote for the election of directors or
(ii) ownership interest,

 

		1.03	“Confidential Information” means any materials or information designated as such in writing by the disclosing
party, whether by letter or by the use of an appropriate proprietary stamp or legend, prior to or at the time any such confidential
or proprietary materials or information are disclosed by the disclosing party to the recipient. Notwithstanding the foregoing,
information or materials which are orally or visually disclosed to the recipient by the disclosing party, or are disclosed in a
writing or other tangible form without an appropriate letter, proprietary stamp or legend, shall constitute Confidential Information
if the disclosing party, within [...***...] after such disclosure, delivers to the recipient a written or electronic
document or documents describing such information or materials, designating the same as confidential, and referencing the place
and date of such oral, visual, written or other tangible disclosure.

 

		1.04	“Field” means treatment of fatty liver disease in humans receiving total parenteral nutrition, by administering,
as monotherapy, a pharmaceutical composition comprising intravenous choline, wherein the fatty liver disease is selected from intestinal
failure-associated liver disease (IFALD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NASH-associated
liver fibrosis, or non-alcoholic cirrhosis.

 

		1.05	“Licensed Product” means any product, process or service in the Field, the development, manufacture, use,
provision or sale of which would, in the absence of the license granted under this Agreement, infringe a Valid Claim of an Agreement
Patent.

 

    -2-

     

    

  

“Net Proceeds”
means all revenues and other consideration received by Licensee in consideration of the grant of a sublicense to the Agreement
Patents and/or an option to sublicense the Agreement Patents, including, without limitation, all upfront fees, license fees, milestone
payments, technology access fees, premiums on sales of debt or equity securities, annual maintenance fees, and any other payments
by a third party in exchange for rights to distribute, market or sell a Licensed Product or an option to distribute, market or
sell a Licensed Product. Net Proceeds does not include: (i) royalties received by Licensee based on Net Sales of Licensed Products
by Sublicensees, or (ii) payments for debt or equity securities of Licensee that are at or below the fair market value of such
securities as of the date of receipt of such payments as mutually determined by Licensor and Licensee.

 

If Licensee intends to accept from a Sublicensee or
optionee any non-cash consideration as Net Proceeds, Licensee must first obtain Licensor’s written approval which approval
shall not be unreasonably withheld or delayed. For any non-cash consideration approved by Licensor and received as Net Proceeds,
the parties will appoint an independent third party to determine the present day value of such consideration and that value shall
be added to Net Proceeds in place of the non-cash consideration. The cost of the independent third party will be paid by Licensee.

 

		1.06	“Net Sales” means the total consideration, in any form, received by Licensee, Affiliates and/or Sublicensees
as consideration for the sale, lease, provision or other disposition of Licensed Products by Licensee and/or Affiliates and/or
Sublicensees to an independent third party (“Total Consideration”) , less:

 

		(a)	customary and reasonable trade discounts actually allowed, refunds, returns and recalls;

 

		(b)	when included in gross sales, customary and reasonable freight, shipping, duties, and sales, V.A.T. and/or use taxes based
on sales prices, but not including taxes when assessed on incomes derived from such sales; and

 

		(c)	Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid, Medicare or similar
local or national government programs.

 

    -3-

     

    

  

In no case will the total deductions referenced in
Sub-sections (a) and (b) of this Section 1.04 exceed [...***...] Percent ([...***...]%) of the Total Consideration
for Licensed Products in any [...***...].

 

If Licensee and/or Affiliates and/or Sublicensees
intend to accept from independent third parties any non-cash consideration as Net Sales or intend, other than in connection with
a clinical trial intended to generate information under a national law which regulates the manufacture, use or sale of drugs, to
provide Licensed Product at no charge, Licensee must first obtain Licensor’s written approval which approval will not be
unreasonably withheld or delayed. For any non-cash consideration approved by Licensor and received as Net Sales, the parties will
appoint an independent third party to determine the present day value of such consideration and that value shall be added to Net
Sales in place of the non-cash consideration. The cost of the independent third party will be paid by [...***...].

 

In the event that, during a particular calendar quarter,
a Licensed Product is sold in combination with one or more other products, whether or not such other products are packaged or otherwise
physically combined with such Licensed Product, for a single price (a “Combination Product”), Net Sales from sales
of a Combination Product, for purposes of calculating royalties due under this Agreement, shall be calculated by multiplying the
Net Sales of the Combination Product by the fraction A/(A+B), where A is the average per unit sales price for such calendar quarter
of the Licensed Product sold separately in the country of sale and B is the average per unit sales price for such calendar quarter
of the other product(s) sold separately in the country of sale. In the event that no separate sales are made of the Licensed Product
and/or the other product(s) in the country of sale, separate sale prices in commensurate countries may be used instead. In the
event that no separate sales are made of the Licensed Product and/or the other product(s), Net Sales from sales of a Combination
Product, for purposes of determining royalty payments on such Combination Products, shall be negotiated in good faith by the parties.
If the parties are unable to agree, then the parties will appoint an independent third party to make the determination. The cost
of the independent third party will be paid by Licensee.

 

    -4-

     

    

  

		1.07	“Patent” means any patent and patent application, including all provisionals, substitutions, divisionals,
reissues, reexaminations, renewals, continuations, continuations-in-part, substitute applications, priority applications and inventors’
certificates, extensions and supplemental certificates and any and all foreign equivalents of the foregoing.

 

		1.08	“Sublicensee” shall mean any non-Affiliate third party to whom Licensee has granted the right to make and
sell (or otherwise dispose of) Licensed Products. A “Sublicensee” shall not include a distributor, pharmacy or other
re-seller of Licensed Products.

 

		1.09	“Territory” means all countries of the world.

 

		1.10	“Valid Claim” means a claim of (a) an issued and unexpired patent which has not been held unenforceable
or invalid by a fin.al, unreversed, and unappealable decision of a court or other governmental body of competent jurisdiction,
has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or finally determined by the relevant governmental
authority to be invalid, unpatentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise; or (b)
a pending patent application to the extent the claim continues to be prosecuted in good faith.

 

		2.	Licensor’s Agreements With U.S. Government

 

		2.01	Licensor, through its research personnel, has and will perform research sponsored in part by the United States Government and
related to the Field. As a result of this government sponsorship of the aforementioned research, the United States Government retains
certain rights in such research as set forth in 35 U.S.C. §200 et seq. and applicable regulations.

 

    -5-

     

    

  

		2.02	The continuance of such government sponsored research by Licensor and its research personnel during the term of this Agreement
will not constitute a breach of this Agreement. All rights reserved to the U.S. Government under 35 U.S.C. §200 et seq.
and applicable regulations shall remain so reserved and shall in no way be affected by this Agreement. Licensor and its research
personnel are not obligated under this Agreement to take any action which would conflict in any respect with their past, current
or future obligations to the U.S. Government as to work already performed and to be performed in the future.

 

		3.	Agreement Patents

 

		3.01	Licensee will pay the cost of maintaining and resisting challenges to the validity of the Agreement Patents using counsel selected
by Licensor. Licensor and Licensee will each have full access to the outside counsel. In the event of disagreement on any patent
matter, Licensor shall have final decision-making authority. Payment is due within [...***...] of receipt of each invoice
for such costs. Licensee shall cooperate with any reasonable request of Licensor in connection with such maintenance and/or defense.
In the event that Licensee elects not to pay to maintain or defend any patent within the Agreement Patents, Licensee shall give
Licensor [...***...] prior written notice of such election. Any patents so elected shall at the end of the notice period
cease to be considered Agreement Patents, and Licensor shall then be free, at its election, to abandon, maintain or enforce such
patent (at Licensor’s sole discretion, cost and expense) or grant rights to such patent to third parties.

 

		3.02	Amounts paid by Licensee pursuant to Section 3.01 will be non-refundable and not creditable against any other payment due to
Licensor.

 

		3.03	Licensor represents and warrants that no Patent claiming priority to the Agreement Patents has been filed in any jurisdiction
other than the United States or is pending in the United States.

 

    -6-

     

    

  

		4.	License Grant

 

		4.01	Subject to Section 2, Licensor hereby grants to Licensee and Affiliates an exclusive license in the Territory, with the right
by Licensee only to grant sublicenses to non-Affiliate third parties, under Licensor’s rights in the Agreement Patents to
develop, make, have made, use, sell, offer for sale and import Licensed Products. Licensee will not grant or amend any sublicense
under Agreement Patents unless it first submits a full and complete draft of any such proposed sublicense or amendment (as the
case may be) to Licensor and then receives the prior written consent of Licensor, which consent will not be unreasonably withheld
or delayed. The terms of any sublicense agreement shall not contradict the terms of this Agreement and shall include (at least)
the following provisions: prohibiting any use of Licensor’s name (consistent with Section 9.01), requiring indemnification
of Licensor (consistent with Section 12.04), requiring appropriate insurance (consistent with Section 12.09), and disclaiming any
warranties or representations by Licensor (consistent with Sections 12.05 and 12.06). Licensee shall provide Licensor with a full
and complete copy of any approved sublicense or amendment within thirty (30) days of execution thereof by Licensee, which sublicense
or amendment shall be the Confidential Information of Licensee and protected from disclosure by Licensor as provided in Section
5.03.

 

		4.02	Notwithstanding the exclusive rights granted to Licensee in the Field pursuant to Section 4.01, Licensor shall retain the right
to make, use and practice Agreement Patents its own laboratories solely for non-commercial scientific purposes and for continued
non-commercial research. Further, Licensor shall have the right to make available to not-for-profit scientific institutions and
non-commercial researchers materials covered under Agreement Patents, solely for non-commercial scientific and research purposes,
provided, however, that no Confidential Information of Licensee is disclosed in the process.

 

    -7-

     

    

  

		4.03	Nothing contained in this Agreement shall be construed or interpreted as a grant, by implication or otherwise, of any license
except as expressly specified in Section 4.01 hereof. The license granted herein shall apply to the Licensee and Affiliates, except
that Affiliates shall not have the right to grant sublicenses. If any Affiliate exercises rights under this Agreement, Licensee
will promptly notify Licensor in writing, and such Affiliate shall be bound by all terms and conditions of this· Agreement,
including but not limited to indemnity and insurance provisions, which shall apply to the exercise of the rights, to the same extent
as would apply had this Agreement been directly between Licensor and the Affiliate. In addition, Licensee shall remain fully liable
to Licensor for all acts and obligations of Affiliates such that acts of Affiliates shall be considered the acts of Licensee.

 

		5.	Confidentiality

 

		5.01	Nothing herein contained shall preclude Licensor from making required reports or disclosures to the NIH or to any other philanthropic
or governmental funding organization, provided, however, that no Confidential Information of Licensee is disclosed in the
process.

 

		5.02	Licensee will retain in confidence Confidential Information of Licensor and Licensee will not disclose any such Confidential
Information to any third party without the prior written consent of Licensor, except that Licensee shall have the right
to disclose such information to any third party for commercial, investment, or research and development purposes under written
terms of confidentiality and non-disclosure which are commercially reasonable. These obligations of confidentiality are for a period
ending five (5) years after termination or expiration of this Agreement, provided, however, that such obligations shall
not apply to any such information which:

 

		(a)	was known to Licensee or generally known to the public prior to its disclosure hereunder as evidenced by written record; or

 

    -8-

     

    

  

		(b)	subsequently becomes known to the public by some means other than a breach of this Agreement; or

 

		(c)	is subsequently disclosed to Licensee by a third party having a lawful right to make such disclosure; or

 

		(d)	is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided
Licensor is given a fair opportunity to defend against such disclosure; or

 

		(e)	is independently developed by Licensee as evidenced by Licensee’s written records without use of or reference to Licensor’s
Confidential Information; or

 

		(f)	Licensee is specifically authorized by Licensor, in writing and in advance, to disclose.

 

		5.03	Licensor will retain in confidence Confidential Information of Licensee and Licensor will not disclose any such Licensee Confidential
Information to any third party without the prior written consent of Licensee for a period ending five (5) years after termination
or expiration of this Agreement, provided however, that such obligations shall not apply to any such information which:

 

		(a)	was known to Licensor or generally known to the public prior to its disclosure hereunder as evidenced by written record; or

 

		(b)	subsequently becomes known to the public by some means other than a breach of this Agreement; or

 

		(c)	is subsequently disclosed to Licensor by a third party having a lawful right to make such disclosure; or

 

		(d)	is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided
Licensee is given a fair opportunity to defend against such disclosure; or

 

    -9-

     

    

  

		(e)	is independently developed by Licensor as evidenced by Licensor’s written records without use of or reference to Licensee’s
Confidential Information; or

 

		(f)	Licensor is specifically authorized by Licensee, in writing and in advance, to disclose.

 

		6.	Royalties and Payments

 

		6.01	Licensee shall make the following payments to Licensor:

 

		(a)	Licensee will pay to Licensor a royalty of One Percent (1.0%) of the first One Hundred Million Dollars ($100,000,000) of Net
Sales and a royalty of One and One-Half Percent (1.5%) of all Net Sales thereafter.

 

		(b)	Licensee will pay to Licensor Twelve and One-Half Percent (12.5%) of Net Proceeds resulting from agreements entered into within
two (2) years from the Effective Date and Seven and One-Half Percent (7.5%) of Net Proceeds resulting from agreements entered into
thereafter.

 

		6.02	Licensee shall make the following license maintenance payments to Licensor:

 

		(a)	On the second anniversary of the Effective Date and every anniversary of the Effective Date thereafter until the first commercial
sale of a Licensed Product, Licensee will pay to Licensor Fifteen Thousand Dollars (US$15,000) as a license maintenance fee. Each
such fee is non-refundable but is creditable against actual payments due to Licensor pursuant to Section 6.01 during the twelve
(12) month period following each such anniversary.

 

		(b)	On the first anniversary of the Effective Date after the first commercial sale of a Licensed Product and every anniversary
of the Effective Date thereafter, Licensee will pay to Licensor Thirty Thousand Dollars (US 30,000) as a license maintenance fee.
Each such fee is non-refundable but is credible against actual payments due to Licensor pursuant to Section 6.01 during the
twelve (12) month period following each such anniversary.

 

    -10-

     

    

  

		6.03	The following one-time Milestone Payments shall be paid by Licensee to Licensor within [...***...] of the occurrence
of the respective Milestone Event:

 

	Milestone Event	Milestone Payment
	[...***...]	$[...***...]
	[...***...]	$[...***...]
	[...***...]	$[...***...]
	[...***...]	$[...***...]

 

		6.04	If a Licensed Product is discontinued in the course of development, only those Milestone Payments that have not been paid at
the time the Licensed Product has been discontinued will be available for payment for a future Licensed Product. Other than as
indicated to the contrary in the preceding sentence, payments made pursuant to Section 6.03 are not creditable against any other
payment due to Licensor.

 

		6.05	Only one royalty will be payable on Net Sales by Licensee and Affiliates and Sublicensees on a Licensed Product under Section
6.01, regardless of the number of Valid Claims in Agreement Patents which cover such Licensed Product. In the event that a Licensed
Product infringes a Valid Claim of a third party Patent covering the manufacture, use or sale of the Licensed Product, [...***...]
Percent ([...***...]%) of royalty payments by Licensee to third parties to make, use or sell the Licensed Product shall
be creditable against royalties payable to Licensor, provided however, that in no event will the royalty payable to Licensor
on any Licensed Product be reduced by more than [...***...] Percent ([...***...]%).

 

		6.06	Licensee’s failure to pay full royalties or make complete payments under Sections 6.01, 6.02 or 6.03 shall be a breach
of this Agreement.

 

    -11-

     

    

  

		7.	Payment Reports and Records

 

		7.01	All payments required to be made by Licensee to Licensor pursuant to this Agreement shall be made to Licensor in U.S. Dollars
by check payable to Licensor and sent to Licensor’s address set out in Section 13.01, with a reference to this Agreement.

 

		7.02	All payments required to be made by Licensee to Licensor pursuant to this Agreement shall be subject to a charge of [...***...]
Percent ([...***...]%) per month or [...***...] Dollars (US$[...***...]), whichever is greater, if
paid more than [...***...] after the date when such payment is due. Conversion of foreign currency to U.S. Dollars shall
be made at the conversion rate quoted by the Wall Street Journal, averaged on [...***...]. [...***...] will
bear any loss of exchange or value and pay any expenses incurred in the transfer or conversion to U.S. Dollars.

 

		7.03	Payments due from Licensee to Licensor pursuant to Section 6.01 will be paid within [...***...] after the end of
each calendar year quarter during which the payment accrued. If no payments pursuant to Section 6.01 are due for any quarter, Licensee
shall send to Licensor a statement to that effect signed by an officer of Licensee. Payment shall be accompanied by a statement
of the number of Licensed Products and Combination Products sold by Licensee, Affiliates and Sublicensees in each country, total
billings for such Licensed Products and Combination Products, the values of A and B used to calculate the Net Sales of Combination
Products, deductions applicable to determine the Net Sales thereof, the amount of Net Sales realized by Licensee and Affiliates
and Sublicensees, the amount of Net Proceeds realized by Licensee, the amount of any deduction and a detailed listing thereof,
and the total payment due from Licensee to Licensor (the “Royalty Report”). Such Royalty Report shall be signed by
an officer of Licensee.

 

		7.04	Licensee and Affiliates shall maintain complete and accurate books of account and records showing Net Sales and Net Proceeds.
Such books and records of Licensee and Affiliates shall be open to inspection, in confidence, during usual business hours, upon
at least [...***...] prior written notice to Licensee, by an independent certified public accountant appointed by Licensor
on behalf of Licensor, who has entered into a written agreement of confidentiality with Licensor which is no less protective of
Licensee’s Confidential Information than the provisions of Section 5.03 hereof and to whom Licensee has no reasonable objection,
for [...***...] years after the calendar year to which they pertain, for the purpose of verifying the accuracy of the
payments made to Licensor by Licensee pursuant to this Agreement. Licensee will require any Sublicensees hereunder to maintain
such books and allow such inspection by Licensee and shall, on request, disclose such information, if available to Licensee, to
Licensor as part of such inspection. Inspection shall be at Licensor’s sole expense and reasonably limited to those matters
related to Licensee’s payment obligations under this Agreement and shall take place not more than once per [...***...].
Any underpayment revealed by any inspection, plus interest on the underpayment amount at the rate of [...***...] Percent
([...***...]%) per [...***...] or [...***...] Dollars (US$[...***...]), whichever is greater,
shall be promptly paid by Licensee to Licensor. Further, if any inspection reveals an underpayment to Licensor of [...***...]
Percent ([...***...]%) or greater, then the cost of the inspection shall be paid by Licensee.

 

    -12-

     

    

  

		8.	Infringement

 

		8.01	Licensee shall have the first right, in its sole discretion and its expense, to enforce and defend the Agreement Patents in
the Field, including initiating legal proceedings on its behalf or in Licensor’s name, if necessary, against any infringer,
or potential infringer, of an Agreement Patent who imports, makes, uses, sells or offers to sell products in the Field. Licensee
shall notify Licensor of its intention to initiate such proceedings at least [...***...] prior to commencement thereof.
Any settlement or recovery received from any such proceeding initiated by Licensee shall be divided [...***...] Percent
([...***...]%) to Licensee and [...***...] Percent ([...***...]%) to Licensor after Licensee deducts
from any such settlement or recovery its actual counsel fees and out-of-pocket expenses relating to any such legal proceeding.
If Licensee decides not to initiate legal proceedings against any such infringer, then Licensor shall have the right to initiate
such legal proceedings. Any settlement or recovery received from any such proceeding initiated by Licensor shall be divided [...***...]
Percent ([...***...]%) to Licensor and [...***...] Percent ([...***...]%) to Licensee after Licensor
deducts from any such settlement or recovery its actual counsel fees and out-of-pocket expenses relating to any such legal proceeding.

 

		8.02	In the event that either party initiates or carries on legal proceedings to enforce any Agreement Patent against an alleged
infringer, the other party shall fully cooperate with and supply all assistance reasonably requested at the expense of the party
requesting such assistance. Further, the other party, at its expense, shall have the right to be represented by counsel of its
choice in any such proceeding. However, if Licensee initiates legal proceedings in Licensor’s name, Licensee shall
reimburse Licensor for any reasonable out-of-pocket counsel fees of Licensor associated with the legal proceedings. The party who
initiates or carries on the legal proceedings shall have the sole right to conduct such proceedings provided, however, that
such party shall consult with the other party to this Agreement prior to entering into any settlement thereof.

 

    -13-

     

    

  

		9.	Prohibition on Use of Names; No Publicity; Publications

 

		9.01	Neither party to this Agreement shall use the name of the other party without the other party’s prior written consent,
except if the use of such name is required by law, regulation, federal securities law, or judicial order, in which event
the party intending to make such announcement will promptly inform the other party, prior to any such required use. Neither party
to this Agreement will make any public announcement regarding the existence of this Agreement and/or the collaboration hereunder
without obtaining the prior written consent of the other party, except if such announcement is required by law, regulation,
federal securities law or judicial order, in which event the party intending to make such announcement will promptly inform the
other party prior to any such required announcement. Each party shall submit any anticipated press release or public disclosure
to the other party, and the receiving party shall expeditiously review and approve any such press release or public disclosure,
which approval shall not be unreasonably withheld or delayed.

 

		9.02	Licensee shall have sole authority to oversee and approve all publications of data arising out of the Licensee’s intravenous
choline product development program.

 

		10.	Term and Termination

 

		10.01	Unless terminated earlier under other provisions hereof, this Agreement will expire upon the expiration of the last to expire
Agreement Patent in the Territory. Upon termination or expiration of this Agreement for any reason, Sections 5, 7, 8, 9, 10.07
through 10.09, 11, 12.01 through 12.10, 12.13, and 13 shall survive and all payment obligations under Sections 3, 5 and 6 hereof
accrued as of the termination date shall be paid by Licensee within thirty (30) days of such termination or expiration.

 

		10.02	Licensee may terminate this Agreement and the licenses granted hereunder by giving notice to Licensor sixty (60) days
                                                                    prior to such termination. Upon such termination, Licensee shall not use Agreement Patents for any purpose and all of Licensee’s rights in Agreement
Patents shall be terminated. Notwithstanding the foregoing, nothing in this Section shall limit Licensee’s ability to practice
the invention(s) which are the subject(s) of the Agreement Patents in any jurisdiction within the Territory where all Agreement
Patents in that jurisdiction shall have expired or all of the claims thereof have been cancelled.

 

    -14-

     

    

  

		10.03	If either Licensor or Licensee defaults on or breaches any condition of this Agreement, the aggrieved party may serve notice
upon the other party of the alleged default or breach. If such default or breach is not remedied within sixty (60) days from the
date of such notice, the aggrieved party may at its election terminate this Agreement. Any failure to terminate hereunder shall
not be construed as a waiver by the aggrieved party of its right to terminate for future defaults or breaches. Licensee’s
damages for any breach of this Agreement by Licensor will be limited to a reduction or suspension of the payment obligations of
Licensee hereunder. Upon termination of this Agreement by Licensor pursuant to this Section 10.03, the licenses granted by Licensor
to Licensee shall terminate and Licensee shall not use Agreement Patents for any purpose and all of Licensee’s rights in
Agreement Patents shall be terminated.

 

		10.04	If Licensee makes an assignment for the benefit of creditors or if proceedings for a voluntary bankruptcy are instituted on
behalf of Licensee or if Licensee is declared bankrupt or insolvent, Licensor may, at its election, terminate this Agreement by
notice to Licensee. Upon termination of this Agreement by Licensor pursuant to this Section 10.04, the licenses granted by Licensor
to Licensee shall terminate and Licensee shall not use Agreement Patents for any purpose and all of Licensee’s rights in
Agreement Patents shall be terminated.

 

		10.05	If Licensee is convicted of a felony relating to the manufacture, use or sale of Licensed Products or a felony relating to
moral turpitude, Licensor may, at its election, terminate this Agreement by notice to Licensee. Upon termination of this Agreement
by Licensor pursuant to this Section 10.05, the licenses granted by Licensor to Licensee shall terminate and Licensee shall not
use Agreement Patents for any purpose and all
of Licensee’s rights in Agreement Patents shall be terminated.

 

    -15-

     

    

 

		10.06	Notwithstanding the provisions of Section 10.03 hereof, should Licensee fail to pay Licensor any sum due and payable under
this Agreement upon thirty (30) days’ written notice, Licensor may, at its election, terminate this Agreement, unless Licensee
pays Licensor within the thirty (30) day period all delinquent sums together with interest due and unpaid. Upon termination of
this Agreement by Licensor pursuant to this Section 10.06, the licenses granted by Licensor to Licensee shall terminate and Licensee
shall not use Agreement Patents for any purpose and all of Licensee’s rights in Agreement Patents shall be terminated.

 

		10.07	Termination of this Agreement by Licensee or Licensor shall not prejudice the rights of either party accruing herein.

 

		10.08	If Licensee terminates this Agreement pursuant to Section 10.02 or 10.03, or if Licensor terminates this Agreement pursuant
to Sections 10.03, 10.04, 10.05 or 10.06, Licensee shall submit a final Royalty Report to Licensor and any payments and patent
costs due to Licensor hereunder as of the date of termination shall be payable within thirty (30) days of the date of termination.

 

		10.09	Notwithstanding any provision herein to the contrary, no termination of this Agreement shall be construed as a termination
of any valid sublicense of any Sublicensee hereunder, and thereafter each such Sublicensee shall be considered a direct licensee
of Licensor, provided that (i) such Sublicensee is not in material breach of its sublicense agreement with Licensee, and
(ii) such Sublicensee agrees in writing to assume all applicable obligations of Licensee under this Agreement.

 

		11.	Amendment and Assignment

 

		11.01	This Agreement sets forth the entire understanding between the parties pertaining to the subject matter hereof.

 

    -16-

     

    

  

		11.02	Except as otherwise provided herein, this Agreement may not be amended, supplemented or otherwise modified, except by
an instrument in writing signed by all parties.

 

		11.03	Without the prior written approval of the other party, which approval shall not be unreasonably withheld, no party may assign
this Agreement except that this Agreement may be assigned to an entity acquiring substantially all of such party’s
business to which this Agreement relates, or in the event of a merger, consolidation, change in control or similar transaction
of such party. Any attempted assignment in contravention of this Section 11.03 shall be null and void.

 

		12.	Miscellaneous Provisions

 

		12.01	This Agreement shall be construed and the rights of the parties governed in accordance with the laws of the State of New York,
excluding its law of conflict of laws. Any dispute or issue arising hereunder, including any alleged breach by any party, shall
be heard, determined and resolved by an action commenced in the state courts in Nassau County, New York or the federal courts in
the Eastern District of New York, which the parties hereby agree shall have proper jurisdiction and venue over the issues and the
parties. Licensor and Licensee hereby agree to submit to the jurisdiction of the state or federal courts in New York and waive
the right to make any objection based on jurisdiction or venue. The New York courts shall have the right to grant all relief to
which Licensor and Licensee are or shall be entitled hereunder, including all equitable relief as any such Court may deem appropriate.

 

		12.02	This Agreement has been prepared jointly.

 

		12.03	If any term or provision of this Agreement or the application thereof to any person or circumstance shall to any extent be
invalid or unenforceable, the remainder of this Agreement or the application of such term or provision to persons or circumstances
other than those as to which it is held invalid or unenforceable shall not be affected thereby and
each term and provision of this Agreement shall be valid and enforced to the fullest extent permitted by law.

 

    -17-

     

    

  

		12.04	Licensee agrees to indemnify Licensor and its current or former directors, governing board members, trustees, officers, faculty,
medical and professional staff, employees, students, trainees and agents and their respective successors, heirs and assigns (Licensor
and each such person being the “Indemnified Parties”) for the cost of defense and for damages awarded and losses and
liabilities incurred, if any, as a result of any third party claims, liabilities, suits or judgments based on or arising out of
the research, development, marketing, manufacture, sale and/or provision of Licensed Products by Licensee, Affiliates and/or Sublicensees,
and/or the licenses granted under this Agreement, or otherwise related to the conduct of Licensee’s, Affiliates’ or
Sublicensees’ business, so long as such claims, liabilities, suits, or judgments are not solely attributable to grossly negligent
or intentionally wrongful acts or omissions by the Indemnified Parties. If a claim, liability, suit or judgment results from the
use of a Licensed Product by Licensor with a patient, and such claim, liability, suit or judgment is solely attributable to negligent
or reckless acts or omissions by the Indemnified Parties, then Licensee shall have no duty to indemnify and defend any of the Indemnified
Parties in connection with such claim, liability, suit or judgment. This indemnity is conditioned upon Licensor’s obligation
to: (i) advise Licensee of any claim or lawsuit, in writing promptly after Licensor or the Indemnified Party has received notice
of said claim or lawsuit, (ii) assist Licensee and its representatives, at Licensee’s expense, in the investigation and defense
of any lawsuit and/or claim for which indemnification is provided, and (iii) permit Licensee to control the defense of such claim
or lawsuit for which indemnification is provided.

 

		12.05	Nothing in this Agreement is or shall be construed as:

 

		(a)	A warranty or representation by Licensor that anything made or used by Licensee under any license granted in this Agreement
is or will be free from infringement of patents, copyrights,
and other rights of third parties; or

 

		(b)	Granting by implication, estoppel, or otherwise any license, right or interest other than as expressly set forth herein.

 

    -18-

     

    

  

		12.06	Except as expressly set forth in this Agreement, the parties MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT. IN ADDITION, NEITHER
PARTY SHALL BE LIABLE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY
AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

 

		12.07	Licensor and Licensee represent and warrant that, to the best of their knowledge, as of the Effective Date:

 

		(a)	they have the legal right and authority to enter into this Agreement and to perform all of their obligations hereunder (including,
without limitation, in the case of Licensor, that it is the owner by assignment of the Agreement Patents);

 

		(b)	when executed by all parties, this Agreement will constitute a valid and legally binding obligation and shall be enforceable
in accordance with its terms; and

 

		(c)	there are no existing or threatened actions, suits or claims pending or threatened against it that may affect the performance
of its obligations under the Agreement. 

 

    -19-

     

    

  

		12.08	Each party represents and warrants that it has not relied on any information provided by the other party, the other party’s
current or former employees or research personnel and has conducted its own due diligence investigation to its satisfaction prior
to entering into this Agreement.

 

		12.09	Licensee represents and warrants that before Licensee, or an Affiliate or a Sublicensee makes any sales of Licensed Products
or performs or causes any third party to perform any clinical trials or tests in human subjects involving Licensed Products, Licensee
or Affiliates or Sublicensees will acquire and maintain in each country in which Licensee or Affiliates or Sublicensees shall test
or sell Licensed Products, appropriate insurance coverage reasonably acceptable to Licensor, but providing coverage in respect
of Licensed Products in an amount no less than [...***...] Dollars (US $[...***...]) per claim. Licensee or
Affiliates will not perform, or cause any third party to perform, any clinical trials or any tests in human subjects involving
Licensed Products unless and until it obtains all required regulatory approvals with respect to Licensed Products in the applicable
countries. Prior to instituting any clinical trials or any tests in human subjects, or sale of any Licensed Product, Licensee shall
provide evidence of such insurance to Licensor. If Licensor determines that such insurance is not reasonably appropriate, it shall
so advise Licensee by written notice delivered not later than [...***...] after it shall have received Licensee’s
evidence of insurance, and, if such notice shall have been delivered within the time permitted therefor, Licensee shall delay such
trials, tests or sales until the parties mutually agree that reasonably appropriate coverage is in place. Licensor shall be listed
as an additional insured in Licensee’s insurance policies. If such insurance is underwritten on a ‘claims made’
basis, Licensee agrees that any change in underwriters during the term of this Agreement will require the purchase of ‘prior
acts’ coverage to ensure that coverage will be continuous throughout the term of this Agreement.

 

		(a)	The minimum amounts of insurance coverage required under this Section shall not be construed to create a limit of Licensee’s
liability with respect to its indemnification under Section 12.04 of this Agreement.

 

    -20-

     

    

  

		(b)	Licensee shall provide Licensor with written evidence of such insurance upon request of Licensor. Licensee shall provide Licensor
with written notice at least [...***...] prior to the cancellation, non-renewal or material change in such insurance;
if Licensee does not obtain replacement insurance providing comparable coverage within such [...***...] period, Licensor
shall have the right to terminate this Agreement effective at the end of such [...***...] period without notice or any
additional waiting periods.

 

		(c)	Licensee shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement
during (i) the period that any product, process or service, relating to, or developed pursuant to, this Agreement is being commercially
distributed or sold or tested in clinical trials by Licensee or by a Sublicensee, Affiliate, optionee or agent of Licensee and
(ii) a reasonable period after the period referred to in (i) above which in no event shall be less than [...***...].

 

		12.10	Licensee shall, and shall cause its Affiliates and Sublicensees to exercise its rights and perform its obligations hereunder
in compliance with all applicable laws and regulations. In particular, it is understood and acknowledged that the transfer of certain
commodities and technical data is subject to United States laws and regulations controlling the export of such commodities and
technical data, including all Export Administration Regulations of the United States Department of Commerce. These laws and regulations,
among other things, prohibit or require a license for the export of certain types of technical data to certain specified countries.
Licensee hereby agrees and gives written assurance that it will comply with all United States laws and regulations controlling
the export of commodities and technical data, that it will be solely responsible for any violation of such by Licensee or
Affiliates or Sublicensees, and that it will defend and hold Licensor harmless in the event of any legal action of any nature occasioned
by such violation.

 

    -21-

     

    

  

		12.11	Licensee agrees it or its Sublicensee(s), as the case may be, shall: (i) obtain all regulatory approvals required for the testing,
manufacture and sale of Licensed Products prior to testing, marketing or selling any such Licensed Products; and (ii) utilize legally
appropriate patent marking on such Licensed Products or printed materials supplied therewith. Licensee agrees to register or record
this Agreement as is required by law or regulation in any country where the license is in effect.

 

		12.12	Licensee agrees that any Licensed Products for use or sale in the United States will be manufactured substantially in the United
States.

 

		12.13	Any tax required to be withheld under the laws of any jurisdiction on royalties payable to Licensor by Licensee under this
Agreement will be promptly paid by Licensee for and on behalf of Licensor to the appropriate governmental authority, and Licensee
will furnish Licensor with proof of payment of the tax together with official or other appropriate evidence issued by the competent
governmental authority sufficient to enable Licensor to support a claim for tax credit with respect to any sum so withheld. Any
tax required to be withheld on payments by Licensee to Licensor will be an expense of and be borne solely by Licensor, and Licensee’s
royalty payment(s) to Licensor following the withholding of the tax will be decreased by the amount of such tax withholding. Licensee
will cooperate with Licensor in the event Licensor elects to assert, at its own expense, exemption from any tax.

 

		12.14	In the event Licensee (or any entity acting under Licensee’s control or on its behalf) initiates any proceeding or otherwise
asserts any claim challenging the validity or enforceability of any of the Agreement Patents in any court, administrative agency
or other forum (“Challenge”), the royalty rates set forth in Section 6.01 and the license maintenance fees set forth
in Section 6.02 shall be automatically doubled on and after
the date of such Challenge for the remaining term of this Agreement. Moreover, to the extent not already covered by Section 3.01,
Licensee agrees to pay all costs and expenses (including actual attorneys’ fees) incurred by Licensor in connection with
defending a Challenge.

 

    -22-

     

    

  

		12.15	Licensee will promptly notify Licensor in writing if Licensee or any Sublicensee is not or ceases to be a [...***...].

 

		12.16	This Agreement may be signed in counterparts, each of which shall be deemed an original and all of which together shall be
deemed one and the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding
when received by the applicable party.

 

		13.	Notices

 

		13.01	All notices required hereunder shall be in writing and shall be sent by a nationally recognized courier service (e.g.,
UPS, Federal Express), with all delivery charges prepaid, and by e-mail, to the parties at their addresses set forth herein or
to such other address(es) as may be furnished by written notice in the manner set forth herein.

 

To Licensee:

 

ArTara Therapeutics, Inc.

302a West 12th Street, Suite 254, New York, NY 10014

Attn: Jesse Shefferman

Chief Executive Officer

E-mail: [...***...]

 

with a copy to:

 

David S. Smith, Esq.

Pepper Hamilton, LLP

500 Grant Street, Suite 5000

Pittsburgh, PA 15219

E-mail: [...***...]

 

    -23-

     

    

 

To Licensor:

 

The Feinstein Institute for Medical Research 350 Community
Drive

Manhasset, NY 11030

Attn: Kirk R. Manogue, PhD

Vice President, Technology Transfer

E-mail: [...***...]

 

with copies to:

 

Kenneth P. George, Esq.

Amster, Rothstein & Ebenstein LLP

90 Park Avenue

New York, NY 10016

E-mail: [...***...]

 

Northwell Health

Office of Legal Affairs 2000 Marcus Avenue

New Hyde Park, NY 11042

E-mail: [...***...]

 

[Remainder of page intentionally blank.
Signature page follows immediately.]

 

    -24-

     

    

  

IN WITNESS WHEREOF, by the signatures of their duly authorized
representatives, the parties have entered into this Agreement effective as of the day and year first above written.

 

	 	THE FEINSTEIN INSTITUTE
    FOR MEDICAL RESEARCH
	 	 
	 	By:	/s/ Kirk R. Manogue
	 	 
	 	Name: Kirk R. Manogue, PhD
	 	 
	 	Title: Vice President, Technology
    Transfer
	 	 
	 	Date: 22DEC2017

 

	 	ARTARA THERAPEUTICS, INC.
	 	 
	 	By:	/s/ Randall D Marshall
	 	 
	 	Name: Randall D Marshall MD
	 	 
	 	Title: Chief Medical Officer
	 	 
	 	Date: 22DEC2017

 

    -25-

     

    

 

APPENDIX A -Agreement Patents

[...***...]

 

    A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]